Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c

Avalanche Biotechnologies (NASDAQ: AAVL) reported Q1 EPS of ($0.57), $0.18 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $265 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• XP Inc. (XP) Tops Q2 EPS by 8c